Vitiligo

Vitiligo is an acquired depigmenting skin disorder characterised by the loss of melanocytes, the pigment-producing cells responsible for skin, hair, and eye colour. Clinically, it presents as well-demarcated milky-white patches on the skin resulting from the absence of melanin.

Vitiligo affects approximately 0.5 to 1% of the global population. About half of affected individuals develop pigment loss before the age of 20, and most cases begin before age 30. A family history is present in approximately 20% of patients, suggesting a genetic predisposition. Males and females are affected equally.

Although vitiligo itself is not typically associated with serious physical illness, individuals with this condition have a higher prevalence of autoimmune conditions, including thyroid disease, type 1 diabetes, Addison disease, pernicious anemia, rheumatoid arthritis, alopecia areata, and psoriasis. For this reason, screening for associated autoimmune disorders may be recommended in selected cases.

This skin condition is widely considered a systemic autoimmune condition involving dysregulation of the innate immune response, leading to melanocyte destruction. Genetic susceptibility also plays a significant role. Environmental triggers such as skin injury (Koebner phenomenon), sunburn, emotional stress, or inflammation may precipitate or worsen the condition.

Understanding Vitiligo: Causes and Symptoms

Depigmented patches may appear anywhere on the body. Common sites include the face, eyelids, neck, fingertips, toes, lips, nipples, navel, body folds such as the axillae, and areas exposed to friction or trauma. Hair within affected areas, including scalp hair, eyelashes, and eyebrows, may also lose pigment. The extent and rate of progression are unpredictable, and may spread over months and then stabilize, with cycles of activity and remission occurring intermittently over time.

This condition is more noticeable in individuals with darker skin tones due to contrast. In lighter skin types, pigment loss often becomes more apparent during summer months when surrounding skin tans.

In 2007, the European Taskforce classified this condition into four categories. Non-segmental type is the most common and presents with bilateral, symmetrical depigmented patches that may be stable or progressive. Segmental type typically appears as a unilateral patch with irregular borders, often affecting younger individuals, and tends to stabilize within six months. Mixed includes features of both segmental and non-segmental types. Unclassified usually represents early or indeterminate presentations.

Diagnosis is primarily clinical. In certain cases, blood tests may be ordered to evaluate thyroid function, vitamin B12 levels, or autoimmune markers to assess for associated conditions.

Treatment remains challenging, and complete repigmentation cannot always be achieved. However, meaningful improvement is possible in many patients. Areas such as the face and trunk tend to respond better to therapy than the hands, feet, or regions with white hair. Early intervention generally yields better outcomes.

Topical therapies, including corticosteroids and calcineurin inhibitors, may be prescribed to reduce inflammation and promote repigmentation, particularly for facial involvement. Phototherapy, particularly narrowband UVB, is a well-established treatment option that helps reduce immune-mediated melanocyte destruction and stimulate repigmentation.